SH2D5 promotes lung adenocarcinoma cell metastasis and triggers EMT via activating AKT signaling pathway

被引：0
作者：
Du, Licheng [1 ]
Ren, Wenjia [1 ]
Liu, Linjun [1 ]
Zhu, Haojia [1 ]
Xu, Ke [2 ]
Zhou, Yubai [1 ]
机构：
[1] Beijing Univ Technol, Dept Biol, Coll Chem & Life Sci, Beijing, Peoples R China
[2] Natl Inst Viral Dis Control & Prevent, NHC Key Lab Biosafety, China CDC, Beijing, Peoples R China
来源：
PLOS ONE | 2024年 / 19卷 / 12期
关键词：
CANCER; PLASTICITY;
D O I：
10.1371/journal.pone.0316432
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Lung adenocarcinoma (LUAD) is the most common histological subtype of lung cancer, characterized by a high incidence in late stages, high mortality rate, and poor prognosis. Src Homology 2 Domain Containing Protein 5 (SH2D5) is a mammalian-specific, uncharacterized scaffolding protein, and its role in LUAD remains unclear. In the present study, we investigated the function and potential mechanisms of SH2D5 in the progression of LUAD. We found aberrant expression of SH2D5 in LUAD tissues and cells, and its high expression is closely associated with poor prognosis in LUAD patients. Through loss-of-function and gain-of-function experiments, we revealed that overexpression of SH2D5 promotes the proliferation and migration abilities of lung adenocarcinoma cells. Gene set enrichment analysis (GSEA) revealed that SH2D5 positively regulates the epithelial-mesenchymal transition (EMT) process in lung adenocarcinoma cells. Additionally, we found that regulating the expression of SH2D5 influenced the phosphorylation levels of AKT, and the rescue experiments with AKT pathway activators/inhibitors partially reversed the tumor progression and EMT processes induced by SH2D5. In summary, our study demonstrated that SH2D5 promotes the migration and EMT process of LUAD cells through the AKT signaling pathway, suggesting that SH2D5 may serve as a crucial potential target for the treatment of metastatic LUAD.
引用
收藏
页数：15
相关论文
共 36 条
  • [1] Bray F, Laversanne M, Sung H, Ferlay J, Siegel RL, Soerjomataram I, Et al., Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries, CA Cancer J Clin, 2024
  • [2] Howlader N, Forjaz G, Mooradian MJ, Meza R, Kong CY, Cronin KA, Et al., The Effect of Advances in Lung-Cancer Treatment on Population Mortality, N Engl J Med, 383, 7, pp. 640-649, (2020)
  • [3] Yang X, Bai Q, Chen W, Liang J, Wang F, Gu W, Et al., m6 A-Dependent Modulation via IGF2BP3/ MCM5/Notch Axis Promotes Partial EMT and LUAD Metastasis, Adv Sci (Weinh), 10, 20, (2023)
  • [4] Hirsch FR, Scagliotti GV, Mulshine JL, Kwon R, Curran WJ, Wu Y-L, Et al., Lung cancer: current therapies and new targeted treatments, Lancet, 389, 10066, pp. 299-311, (2017)
  • [5] Gettinger S, Horn L, Jackman D, Spigel D, Antonia S, Hellmann M, Et al., Five-Year Follow-Up of Nivolumab in Previously Treated Advanced Non-Small-Cell Lung Cancer: Results From the CA209-003 Study, J Clin Oncol, 36, 17, pp. 1675-1684, (2018)
  • [6] Hao D, Han G, Sinjab A, Gomez-Bolanos LI, Lazcano R, Serrano A, Et al., The Single-Cell Immunogenomic Landscape of B and Plasma Cells in Early-Stage Lung Adenocarcinoma, Cancer Discov, 12, 11, pp. 2626-2645, (2022)
  • [7] Stemmler MP, Eccles RL, Brabletz S, Brabletz T., Non-redundant functions of EMT transcription factors, Nat Cell Biol, 21, 1, pp. 102-112, (2019)
  • [8] Nieto MA., The ins and outs of the epithelial to mesenchymal transition in health and disease, Annu Rev Cell Dev Biol, 27, pp. 347-376, (2011)
  • [9] Yang J, Antin P, Berx G, Blanpain C, Brabletz T, Bronner M, Et al., Guidelines and definitions for research on epithelial-mesenchymal transition, Nat Rev Mol Cell Biol, 21, 6, pp. 341-352, (2020)
  • [10] Huang Y, Hong W, Wei X., The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis, J Hematol Oncol, 15, 1, (2022)
1234